Compare
Freenome, Inc. vs Biodesix Inc vs Sera Prognostics, Inc. vs Exagen Inc.
| Latest fiscal year | Freenome, Inc. FRNM | Biodesix Inc BDSX | Sera Prognostics, Inc. SERA | Exagen Inc. XGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $88.50M | $81.0K | $66.58M |
| Revenue growth (YoY) | n/a | +24.1% | +5.2% | +19.7% |
| Gross margin | n/a | n/a | -102.5% (computed) | 58.3% |
| Operating margin | n/a | -31.5% | n/m | -21.1% |
| Net margin | n/a | -39.8% | n/m | -30.0% |
| Net income | $837.5K | -$35.27M | -$31.93M | -$19.95M |
| EPS (Diluted) | n/a | -$4.67 | -$0.67 | -$0.93 |
| Operating cash flow | -$864.7K | -$23.27M | -$25.62M | -$13.62M |
| Free cash flow | n/a | -$23.53M | -$26.35M | -$14.27M |
| Cash & equivalents | n/a | $18.99M | $3.94M | $32.22M |
| Total assets | $92.78M | $87.48M | $101.93M | $58.02M |
| Total liabilities | $5.70M | $89.94M | $26.52M | $40.57M |
| Shareholders' equity | -$4.80M | -$2.46M | $75.41M | $17.45M |
| Return on year-end equity | n/a | n/a | -42.3% | -114.3% |
| Shares outstanding | n/a | 8.25M | n/a | 22.91M |
Revenue, most recent five fiscal years
| Fiscal year | Freenome, Inc. | Biodesix Inc | Sera Prognostics, Inc. | Exagen Inc. |
|---|---|---|---|---|
| Latest | n/a | $88.50M Ended 2025-12-31 | $81.0K Ended 2025-12-31 | $66.58M Ended 2025-12-31 |
| 1 year earlier | n/a | $71.32M Ended 2024-12-31 | $77.0K Ended 2024-12-31 | $55.64M Ended 2024-12-31 |
| 2 years earlier | n/a | $49.09M Ended 2023-12-31 | $306.0K Ended 2023-12-31 | $52.55M Ended 2023-12-31 |
| 3 years earlier | n/a | $38.21M Ended 2022-12-31 | $268.0K Ended 2022-12-31 | $45.56M Ended 2022-12-31 |
| 4 years earlier | n/a | $54.51M Ended 2021-12-31 | $82.0K Ended 2021-12-31 | $48.30M Ended 2021-12-31 |